Research & Development



Technology Platform

  • Target Specific and Long-acting Delivery of Proteins

  • Neutralizing Antibodies Discovery

  • Industrialization of Recombinant Proteins and Antibodies

  • Design of Novel Small-molecule Antivirals

Dr. Tao Wang


The CSO of Beijing Kawin Technology and the CEO of Kawin Biosciences USA

Dr. Wang received B.S. degree in Organic Chemistry from Peking University in 1990 and Ph.D. degree in Organic Chemistry from New York University in 1996. From 1996 to 1998, he was a postdoctoral associate with Professor Gilbert Stork at Columbia University.

From 1998 to 2021, Dr. Wang led the discovery of new antiviral and immune-oncology medicines in Bristol-Myers Squibb Co. (BMS), both small molecules and peptides. Dr. Wang has been the recipient of several awards from BMS, including Chemistry Leadership Award, The President’s Award, and Innovation Award.

Among Dr. Wang’s multiple clinical compounds, RukobiaTM (fostemsavir) was approved by FDA in July 2020 and by EMA in February 2021.

In 2022, Dr. Wang was invited by University of Texas Medical Branch, Texas, USA, to be a Tenured Full Professor.

In 2023, Dr. Wang received ACS Hero of Chemistry Award from American Chemical Society of USA.

In 2024, Dr. Wang was honored with Consulting Professor by Sun Yat-sen University.

Dr. Wang is the inventor of 113 filed patent applications, among which 76 have been granted in US. Dr. Wang has co-authored 45 peer-reviewed research articles and 7 reviews.

Dr. Wang’s current responsibilities in Kawin include: 1) overseeing R&D research center, 2) managing Kawin USA subsidiary, 3) building pipeline, 4) fostering external collaborations, and 5) participating in investing activities.





+86 10 87120888